Nosopharm

Nosopharm is an innovative biotechnology company specialized in the research and development of new molecules to combat antimicrobial resistance (AMR).

[Nosopharm @Nosopharm]

Nosopharm has been selected for the new French Tech Health20 program for its contribution in the fight against emerging infectious diseases and #AntimicrobialResistance
https://t.co/RDQHi17FPn

[Nosopharm @Nosopharm]

Nosopharm est lauréate de la 1ère promotion du French Tech #Health20 !

🔬Le programme d'accompagnement de @LaFrenchTech et l’AIS dédié aux #startup prometteuses de la #healthtech

Pour en savoir plus sur le programme 👉 https://t.co/m27gyalXqC

[Nosopharm @Nosopharm]

We are featured in a nice article in @DrugDiscovNews ! #Odilorhabdin #NOSO502 https://t.co/4l4hHQ19wN

[Nosopharm @Nosopharm]

Nosopharm wishes you a great and successful new year 2023!!!

[IMI AMR ACCELERATOR @AMRAccelerator]

New publication by members of the GNA NOW Consortium based on work done under the Consortium's NOSO-502 program – a first-in-class Odilorhabdin antibiotic that has the potential to treat life-threatening multidrug-resistant infections 👇 https://t.co/zFQMNhItmP @IHIEurope

[Nosopharm @Nosopharm]

Our new scientific publication about our first-in-class #Odilorhabdin antibiotic #NOSO502 is just released: https://t.co/m3anJzFyYS
Great collaboration with @Inserm U1230 and U1311, and @NorthBristolNHS !

[Nosopharm @Nosopharm]

Nosopharm welcomes new members to its Supervisory Board: Jacques Dumas, Laurent Fraisse (@fraisse47), Sandra Dubos (@sandra_dubos), and Martin Lauriot Prevost.

https://t.co/6V9i97gNPo

[Nosopharm @Nosopharm]

Our CEO, Philippe Villain-Guillot @PVG_NOSOPHARM , presented our unique anti-infective drug discovery platform and pipeline yesterday at #BIO2022

[Nosopharm @Nosopharm]

Nosopharm is attending #BIO2022 next week in San Diego, CA (USA)!
https://t.co/go2iSUEQCs

[Nosopharm @Nosopharm]

"It proves that this kind of work can be done collaboratively by partners from academia, industry and big pharma. Together, it is possible to achieve positive results during the notoriously challenging early stages of antibiotic development." 2/2

[Nosopharm @Nosopharm]

Dr. Lynn Silver @lynnnj :
"The positive results of the NOSO-502 program demonstrate the importance of discovery and development partnerships like the GNA NOW Consortium." 1/2

[Nosopharm @Nosopharm]

Notre nouveau candidat antibiotique NOSO-502 franchit un jalon important grâce au consortium GNA NOW! https://t.co/RH6LGt86Y5

@Evotec @lygature @BIOASTER @Helmholtz_HZI @NorthBristolNHS @LivUni @Inserm @ErasmusMC @MedUni_Wien @Fraunhofer_en @IHIEurope @EFPIA @AMRAccelerator

[Nosopharm @Nosopharm]

Our first-in-class #Odilorhabdin antibiotic NOSO-502 reaches an important milestone thanks to GNA NOW! https://t.co/FBU6ZnilV1

@Evotec @lygature @BIOASTER @Helmholtz_HZI @NorthBristolNHS @LivUni @Inserm @ErasmusMC @MedUni_Wien @Fraunhofer_en @IHIEurope @EFPIA @AMRAccelerator

[Nosopharm @Nosopharm]

Nosopharm is a proud member of @AllianceBEAM . @AllianceBEAM just released a great short video about the urgent needs of the SMEs to deliver innovation in #antimicrobialresistance. Don't hesitate to spread the message around you! #AMRSMEsvoice
https://t.co/R732ZoG7o5

[BEAM Alliance @AllianceBEAM]

The #EU Pharma Legislation revision is on the horizon. What solutions do #SMEs need from our policymakers to unlock the innovation potential to tackle #AMR? Check out this video and don’t hesitate to spread the voice of SMEs too: like, share, and comment! https://t.co/h4SSOHkcWB

[Nosopharm @Nosopharm]

Nosopharm will attend the 6th #AMRConference next week in Basel. We are looking forward to meeting you there! @AMR_Conference
https://t.co/GLJRDp3ECh

[Nosopharm @Nosopharm]

Nosopharm is attending #BIOEuropeSpring 2022!
https://t.co/x2oriFZgUn

[Nosopharm @Nosopharm]

Notre nouveau projet de recherche collaboratif avec @INRAE_UMR_DGIMI @INRAE_France @umontpellier a été sélectionné pour bénéficier du soutien financier de #FranceRelance: https://t.co/kwlHbxwg37
@Economie_Gouv @sup_recherche

[Nosopharm @Nosopharm]

Our new collaborative research project with @INRAE_UMR_DGIMI @INRAE_France @INRAE_Intl @umontpellier is financially supported by #FranceRelance: https://t.co/kwlHbxwg37
@Economie_Gouv @sup_recherche

[Nosopharm @Nosopharm]

Nous sommes ravis d'annoncer une nouvelle collaboration de recherche avec @INRAE_UMR_DGIMI @INRAE_France @umontpellier : https://t.co/bPRYs6LLb1
#antibioresistance

[Nosopharm @Nosopharm]

We are thrilled to announce a new research collaboration with @INRAE_UMR_DGIMI @INRAE_Intl @INRAE_France @umontpellier : https://t.co/u95ubTW6si
#AntimicrobialResistance